Fracture Of Humerus In A Newborn During Cesarean Section: A Case Report

Risk of birth injuries and long bone fractures are common in vaginal breech deliveries but have also occurred in the cesarean section. Here, we report the case of a term neonate who was admitted with swelling and paucity of movement of the right arm with a history of energetic traction during the emergency cesarean section. The diagnosis was confirmed by radiography and managed by plaster of paris slab. Obstetrician and pediatrician should remain vigilant regarding such rare complications so that these cases are not overlooked, as timely intervention and management are necessary to prevent disability and deformities in the future.

Evaluation of Satb1, Survivin, and Ki-67 as Possible Markers to Differentiate Phyllodes Tumour from Fibroadenoma

Aims Difficulties in diagnosis of phyllodes tumour are well known. Our aim was to observe whether the expressions of satb1, survivin, and ki-67 were helpful in differentiating fibroadenoma and phyllodes tumour. Settings and design Retrospective. Methods and material Paraffin embedded tissue samples from 60 female patients with phyllodes tumour and 60 female patients with fibroadenoma were studied. Expression of the gene products was studied and confirmed using immunohisto chemical and western blot analysis. Statistical analysis used The statistical analysis was performed using Fisher's exact test to find out the significant changes. Results Statistically significant difference was observed in Satb1, survivin expression between fibroadenoma and benign phyllodes cases. The difference between the Ki-67 expression in fibroadenoma and benign phyllodes cases was not statistically significant. Conclusions Our finding of strong stromal expression of satb1 and survivin in phyllodes as compared to fibroadenoma can be helpful for the development of additional diagnostic and prognostic indicators for otherwise difficult cases. Such immunochemical markers can be used to elucidate cellular basis of tumour behaviour. Validation of such immunochemical test in future will reduce diagnostic uncertainty in this rare tumour. In addition to that such parameters may serve as a therapeutic target that could increase effectiveness of chemotherapy or radiation therapy. A study with large number of samples along with clinical and follow-up data is required for confirmation.